Prostate Specific Antigen antibody (AA 220-250)
Quick Overview for Prostate Specific Antigen antibody (AA 220-250) (ABIN1537679)
Target
See all Prostate Specific Antigen (PSA) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 220-250
-
Purification
- Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.
-
Immunogen
- This HKLK3 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 220-250 amino acids from human HKLK3.
-
Isotype
- IgM
-
-
-
-
Application Notes
- WB: 1:500~1600
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Mouse monoclonal antibody supplied in crude ascites with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- HKLK3 Antibody (C234) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, keep at -20 °C.
-
Expiry Date
- 6 months
-
-
- Prostate Specific Antigen (PSA)
-
Background
- Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
-
Molecular Weight
- 28741
-
Gene ID
- 354
-
NCBI Accession
- NP_001025218, NP_001025219, NP_001639
-
UniProt
- P07288
-
Pathways
- Complement System
Target
-